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Background: We aimed to detect CD40 mutant expression and evaluate its clinical significance in gastric cancer.
Methods: CD40 mutant expression in 78 cases of gastric cancer tissues, 10 cases of normal gastric tissues, and 10
cases of gastric adenoma tissues by immunohistochemical test. Survival analyses were also performed.
Results: The positive CD40 mutant rate in gastric cancer was 55.1% (43/78). No positive CD40 mutant staining was
observed in the normal gastric tissue or the gastric adenoma. CD40 mutants expression was significantly correlated
with invasive depth, lymph metastasis, and TNM stage (P <0.05). Cases with negative CD40 mutant expression
had a significantly longer median survival time than those with positive CD40 mutant expression (40 vs. 14 months,
P <0.05). A lower death risk in negative CD40 mutant cases was observed comparing with positive CD40
mutant cases.
Conclusions: Positive CD40 mutant expression suggests a poorer prognosis of gastric cancer cases.
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Gastric cancer is the second leading cause of cancer-related
death worldwide, with the highest incidence in Eastern Asian
and Eastern European countries [1-3]. It was estimated that
989,000 new cases and 738,000 deaths had occurred world-
wide in 2008 alone, which accounted for 8% of the total new
cases and 10% of the total cancer-related deaths [3].
With the advances in molecular biology, much progress
has been achieved in our understanding of the molecular
pathogenesis of cancer. CD40 is a cell surface receptor
that belongs to the tumor necrosis factor-receptor super-
family, originally identified in T cells. CD40 was first iden-
tified and functionally characterized on B lymphocytes
[4,5]. Later reports revealed that the expression of CD40
was not restricted to B cells but that it was also expressed
on monocytes, dendriticcell, and on non-hematopoietic* Correspondence: jimei90@sina.com; wcpzlk@163.com
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thelial, epithelial, and tumor cells.
CD40 is a crucial member of the group of co-stimulating
molecules, orchestrating both humoral and cell-mediated
immune responses, and is closely related with tumor inva-
sion and metastasis [5,6]. CD40 provides a conduit through
which the immune system can suppress growth and induce
apoptosis of CD40-expressing epithelial cancers [7].
CD40 mutant (CAC→ CAA, 78His→ 78Gln, NCBI
Assay ID: ss23134804, Reference SNP ID: rs17177493) is
a variant type of CD40 found on the surface of the U266
cell line and in freshly isolated tumor cells. The mutated
residue of this mutant locates in a region which is im-
portant for binding to CD40L. CD40 mutant is translo-
cated to the CD40 signalosome and involved in CD40
signal transduction. It has been reported that CD40 mu-
tant alters partial epitope of CD40 and has a different
ability to combine with antibodies combining with wild-
type CD40, indicating that CD40 mutant might play an
important role in tumor development. CD40 mutant can
also be considered as a possible target for anti-cancer
immunotherapy [8]. However, the mechanisms of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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The present study aimed to examine the CD40 mu-
tant expression in gastric cancer tissues and investigate




A total of 78 gastric cancer patients diagnosed as gastric
cancer by after-operation pathological examinations were
enrolled between 1 January 2002 and 31 December 2005
in The Third Affiliated Hospital of Soochow University in
China. No patients received radiotherapy or chemother-
apy before the enrollment. Moreover, those who had sec-
ondary malignancies were excluded. Of the 78 cases, 58
were men and 20 were women (age range, 28 to 77 years;
average age, 55 years). From 2004 to 2005, the 10 cases of
normal gastric tissue, with four cases of male and six cases
of female normal gastric tissue (age range, 51 to 77 years;
average age, 58 years), and 10 cases of gastric adenoma
(age range, 55 to 67 years; average age, 60 years), were ob-
tained from outpatients. The 78 cases consisted of 43
cases of well/moderate differentiation types (papillary
adenocarcinoma, well-differentiated tubular adenocarcin-
oma, moderately differentiated tubular adenocarcinoma)
and 35 cases of poor differentiation types (poor-differenti-
ated tubular adenocarcinoma, signet ring cell carcinoma,
mucinous carcinoma) according to Kloppel criteria [9].
According to the Response Evaluation Criteria in Solid
Tumors criteria (version 1.1), there were 17 cases of stage
I or II, and 61 cases of stage III or IV. Every patient, en-
rolled in this study, signed a written informed consent
form approved by the Medical Ethics Committee of Soo-
chow University, which also approved the study protocol.
Immunohistochemistry
Antibody to CD40 mutant protein was purchased from
the Institute of Medical Biotechnology, Soochow Univer-
sity. Diaminobenzidine staining kit was purchased from
Fuzhou Maixin Biotechnology Limited Cooperation.
Elivision method was used. For the immunohistochemi-
cal study, formalin-fixed, paraffin embedded tissue sam-
ples from all cases were obtained from patients who
underwent surgeries at our hospital. For CD40 mutant im-
munostaining with goat polyclonal antibodies, tissue sec-
tions (5 μm) were deparaffinized in xylene and rehydrated
in an ethanol series. The sections were then treated for
30 min with 0.3% hydrogen peroxide to block endogen-
ous peroxidase activity, then subsequently washed with
phosphate-buffered saline (PBS) and unmasked in cit-
rate antigen unmasking solution in an autoclave for
20 min at 120°C. The sections were incubated with goat
serum for 15 min at room temperature and then wereincubated with the primary antibodies for 1 h at room
temperature. The bound primary antibodies were de-
tected by adding anti-mouse secondary antibodies and
avidin/biotin/horseradish peroxidase complex for 30 min
at room temperature. The sections were visualized using
solid diaminobenzine diluted in PBS, counterstained with
Mayer’s hematoxylin, and finally mounted. After that, they
were incubated with HRP-labeled anti-mouse immuno-
globulin G as the secondary antibody. Substrate chromo-
gen was added and the specimens were counterstained
with hematoxylin.
Three independent investigators assessed CD40 mutant
positivity semi-quantitatively without prior knowledge of
the clinical follow-up data. Every slice was observed for
representative visual fields randomly. Brown granules as
considered as positive CD40 mutant staining mainly on
the cytoplasmic membrane, and it was also considered as
positive staining while cytoplasm was stained. The inten-
sity of cytoplasmic staining was graded into two easily re-
producible subgroups: a. negative (−): the percentage of
CD40 mutant positive cells <25% or no detectable color-
ation; b. positive (+): ≥25%.
Statistical analysis
All statistical analyses were performed using SPSS 13.0
software (SPSS, Inc.). Correlations between clinicopatho-
logic variables and CD40 mutant levels were compared by
the rank sum tests (two-group analysis using the Wilcoxon
test and multigroups analysis using the Kruskal-Wallis
test). Chi-square test was used to compare the categorical
data. COX model was used to evaluate the strength of the
association between CD40 mutant expression and death.
Kaplan-Meier method was used to calculate the overall
survival time (OST). Log-rank test was used to compare
the OST. P values <0.05 were considered significant.
Results
CD40 mutant expression
The positive CD40 mutant rate in gastric cancer was
55.1% (43/78). No positive CD40 mutant staining was ob-
served in the 10 cases of normal gastric tissue or the 10
cases of gastric adenoma (Figure 1).
Association between CD40 mutant expression and
clinicopathological characteristics
The positive rate of CD40 mutant expression: (1) in cases
with tumor invasion to deep muscle layer was significantly
higher than that in cases with tumor invasion not to
deep muscle layer (61.8% vs. 10%, χ2 = 9.444, P = 0.002);
(2) in cases with lymph node metastasis was signifi-
cantly higher than that in cases without lymph node
metastasis (65% vs. 37%, χ2 = 7.802, P = 0.005); (3) in
cases of stage III and IV was significantly higher
than that in cases of stages I and II (63.9% vs. 23.5%,
Figure 1 Expression of CD40 mutant molecule in various tissue. (A) Positive expression of CD40 mutant molecule in gastric cancer tissue
(×200) (B) Negative expression of CD40 mutant molecule in gastric cancer tissue (×200) (C) Negative expression of CD40 mutant molecule in
normal gastric tissue (×200) (D) Negative expression of CD40 mutant molecule in gastric adenoma tissue (×200).
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pression was not correlated with sex, age, tumor size,
or pathological differentiation (P >0.05) (Table 1).
Survival analysis
The median overall survival time of cases with negative
CD40 mutant expression was significantly longer than
that of cases with positive negative CD40 mutant expres-
sion (40 vs. 14 months, 95% CI 30.6-49.4 and 6.7-21.3,
respectively, χ2 = 14.229, P <0.001) (Figure 2).
COX model analysis
A lower death risk in negative CD40 mutant cases was
observed comparing with positive CD40 mutant cases
after sex, age, depth of tumor invasion, and lymph node
metastasis were adjusted (HR = 0.383, 95% CI 0.227-
0.646, P <0.001).
Discussion
To the best of our knowledge, there have not been any
reports on CD40 mutant expression in gastric cancer
cases, normal gastric tissues, and gastric adenoma.
Several studies found that CD40 expression was signifi-
cantly correlated with lymph node metastasis and distant
metastasis as well as TNM stage, meanwhile patients with
positive CD40 mutant expression had a poorer prognosis
[10,11].
Our results also suggest that CD40 mutant may be an
important factor influencing gastric cancer patients’survival time, which suggests that CD40 mutant may be
an independent negative-regulating molecule influencing
the prognosis of gastric cancer.
Furthermore, no positive CD40 mutant staining was
observed in normal gastric tissues or gastric adenoma
tissues, hence there is a possibility that CD40 mutant is
considered as a tumor biomarker for differentiating ma-
lignant and benign tumors. We have reason to believe
that CD40 mutant level in patients’ serum can be de-
tected to observe the correlation with that in tissues, but
further studies with a larger sample size should be per-
formed to confirm the liability.
Choudhury et al. [12] found that CD40 could transmit
the signals which induced apoptosis. We reckon that
tumor cells inhibit T lymphocytes activation by express-
ing CD40 mutants to escape from immune monitoring.
Our results reveal that there is correlation between
CD40 mutant expression and the stages of gastric cancer
as well as the prognosis, implying a possibility that the
specific antibody of CD40 mutant may induce the apop-
tosis of gastric cancer cells, which means that CD40 mu-
tant could be considered as a new target for tumor
immunotherapy and immune intervention. By using anti
CD40 antibody or CD40 siRNA, this possible target
could be done in vitro first and then confirmed on ani-
mal models before being enrolled into clinical trials.
We believe that CD40 mutant plays an important role
in mediating and regulating the biological behaviors of
gastric cancer cells, and moreover may be a novel target
Figure 2 Overall survival curves for gastric cancer patients. The
median overall survival time of cases with negative CD40 mutant
expression is significantly longer than that of cases with positive
negative CD40 mutant expression (40 vs. 14 months, 95% CI
30.6-49.4 and 6.7-21.3, respectively, χ2 = 14.229, P <0.001).
Table 1 Association between gastric cancer patients’ clinicopathological characteristics s and CD40 mutant levels in
tumor tissues (n = 78)
Characteristics Cases CD40 mutant expression χ2 P
Positive Negative
Sex
Male 58 33 25 0.286 0.593
Female 20 10 10
Age (years)
≥60 48 36 12 2.849 0.091
<60 30 17 13
Tumor size (cm)
≥5 37 20 17 0.033 0.856
<5 41 23 18
Differentiation
Well/moderate 43 20 23 2.074 0.15
Poor 35 22 13
Depth of tumor invasion
Not to deep muscle layer 10 1 9 9.444 0.002a
Deep muscle layer 68 42 26
Lymph nodes metastasis
Yes 60 39 21 7.802 0.005a
No 18 5 13
TNM stage
I and II 17 4 13 8.774 0.003a
III and IV 61 39 22
aP <0.05.
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present preliminary study includes a great heterogenicity
of the enrolled patients to evaluate the prognosis of pa-
tients with gastric cancer, and the role of CD40 mutant
needs to be confirmed. The more exact functions and
mechanisms require progressive studies and the clinical
significance of CD40 mutant should be proved by more
randomized, controlled clinical trials with larger enrolled
case sizes.
Abbreviations
OST: Overall survival time; PBS: Phosphate-buffered saline.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WQZ and XDL performed the experiments. HBS analyzed the data. JW and
JMZ wrote the manuscript. WQZ and XDL helped with manuscript editing.
CPW and MJ provided the study concept and guided the writing. All authors
read and approved the final manuscript.
Authors’ information
Wei-Qing Zhao and Xiao-Dong Li are the co-first authors.
Zhao et al. World Journal of Surgical Oncology 2014, 12:167 Page 5 of 5
http://www.wjso.com/content/12/1/167Acknowledgements
This work was funded by grants from the Jiangsu Health International
Exchange Supporting Program provided by Xiao-Dong Li.
Received: 19 March 2014 Accepted: 6 May 2014
Published: 28 May 2014
References
1. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003, 362:305–315.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2008,
2008(127):2893–2917.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
4. Clark EA, Ledbetter JA: Activation of human B cells mediated through two
distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl
Acad Sci U S A 1986, 83:4494–4498.
5. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2–17.
6. Schonbeck U, Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life
Sci 2001, 58:4–43.
7. Hess S, Engelmann H: A novel function of CD40: induction of cell death
in transformed cells. J Exp Med 1996, 183:159–167.
8. Qi CJ, Zheng L, Ma HB, Fei M, Qian KQ, Shen BR, Wu CP, Vihinen M, Zhang
XG: A novel mutation in CD40 and its functional characterization. Hum
Mutat 2009, 30:985–994.
9. Bajtai A, Hidvegi J: The role of gastric mucosal dysplasia in the
development of gastric carcinoma. Pathol Oncol Res 1998, 4:297–300.
10. Lo SS, Wu CW, Chi CW, Li AF, Chen JH, Lui WY: High CD40 expression in
gastric cancer associated with expanding type histology and liver
metastasis. Hepatogastroenterol 2005, 52:1902–1904.
11. Li R, Chen W-C, Pang X-Q, Tian W-Y, Wang W-P, Zhang XG: CD40 signal
expression in gastric cancer tissue and its correlation with prognosis of
gastric cancer patients. Mol Biol Rep 2012, 39:8741–8747.
12. Choudhury JA, Russell CL, Randhawa S, Young LS, Adams DH, Afford SC:
Differential induction of nuclear factor-κB and activator protein-1 activity
after CD40 ligation is associated with primary human hepatocyte
apoptosis or intrahepatic endothelial cell proliferation. Mol Biol Cell 2003,
14:1334–1345.
doi:10.1186/1477-7819-12-167
Cite this article as: Zhao et al.: CD40 mutant expression and its clinical
significance to prognosis in gastric cancer patients. World Journal of
Surgical Oncology 2014 12:167.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
